SG11201807040WA - N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer - Google Patents
N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancerInfo
- Publication number
- SG11201807040WA SG11201807040WA SG11201807040WA SG11201807040WA SG11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- quinolin
- imidazo
- propan
- pyridyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 111110111010111011101110rn I MEV III International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....1 WO 2017/174446 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CO7D 471/04 (2006.01) A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/437 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/EP2017/057624 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 30 March 2017 (30.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 1605958.6 7 April 2016 (07.04.2016) GB GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: ASTRAZENECA AB [SE/SE]; 151 85 Soder- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, talje (SE). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: BARLAAM, Bernard, Christophe; As LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, traZeneca Alderley Park, Macclesfield Cheshire SK10 4TG SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (GB). PIKE, Kurt, Gordon; AstraZeneca, Darwin Build- GW, KM, ML, MR, NE, SN, TD, TG). ing, Cambridge Science Park Milton Road, Cambridge Declarations under Rule 4.17: Cambridgeshire CB4 OWG (GB). — as to applicant's entitlement to apply for and be a granted (74) Agent: JONES, Teyrnon; ASTRAZENECA INTELLEC- patent (Rule 4.1700) TUAL PROPERTY, Mereside, Alderley Park, Maccles- Published: field Cheshire SK10 4TG (GB). (81) — Designated States (unless otherwise indicated, for every with international search report (Art. 21(3)) kind of national protection available): AE, AG, AL, AM, (54) Title: N,N-DIMETHYL-3-[[5-(3-METHYL-2-0X0-1-TETRAHYDROPYRAN-4-YL-IMIDAZO[4,5-C]QUINOLIN-8-YL)-2- . PYRIDYL]OXY]PROPAN-1-AMINE OXIDE AS ATM (ATAXIA TELANGIECTASIA MUTATED) KINASE MODULATOR FOR TREATING = CANCER O C H 3 H 3 C\" N+ 1 ..-\"*---------'° 0 - 1-1 .4 \ — C H 3 71' 0 10 71' 71' N IN 1-1 IN 1-1 (I) 0 ei (57) : The specification generally relates to the compound of Formula (I), i.e. to N,N-dimethy1-34[5-(3-methy1-2-oxo-l-tet - 0 rahydropyran-4-yl-imidazo[4,5-c]quinolin-8-y1)-2-pyridyl]oxy]propan-l-amine oxide as ATM (ataxia telangiectasia mutated) kinase modulator for treating cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605958 | 2016-04-07 | ||
| PCT/EP2017/057624 WO2017174446A1 (en) | 2016-04-07 | 2017-03-30 | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807040WA true SG11201807040WA (en) | 2018-09-27 |
Family
ID=58461335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807040WA SG11201807040WA (en) | 2016-04-07 | 2017-03-30 | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190119270A1 (en) |
| EP (1) | EP3440079A1 (en) |
| JP (1) | JP2019513730A (en) |
| KR (1) | KR20180132804A (en) |
| CN (1) | CN108834414A (en) |
| AU (1) | AU2017247558A1 (en) |
| BR (1) | BR112018070229A2 (en) |
| CA (1) | CA3015953A1 (en) |
| EA (1) | EA201891866A1 (en) |
| IL (1) | IL261558A (en) |
| MA (1) | MA44603A (en) |
| MX (1) | MX2018012255A (en) |
| SG (1) | SG11201807040WA (en) |
| WO (1) | WO2017174446A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045042A (en) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Application of the ATM inhibitor in the drug that preparation inhibits acute lymphatic leukemia recurrence |
| JP2023539715A (en) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | Combination of antibody-drug conjugates and ATM inhibitors |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| ATE211134T1 (en) | 1996-03-05 | 2002-01-15 | 4-ANILINOQUINAZOLINE DERIVATIVES | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CN103030637A (en) * | 2011-10-10 | 2013-04-10 | 上海恒瑞医药有限公司 | Imidazole quinoline derivative, and pharmaceutically acceptable salts thereof, preparation method thereof and application thereof on medicines |
| NO2714752T3 (en) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-30 EP EP17714741.0A patent/EP3440079A1/en not_active Withdrawn
- 2017-03-30 WO PCT/EP2017/057624 patent/WO2017174446A1/en active Application Filing
- 2017-03-30 AU AU2017247558A patent/AU2017247558A1/en not_active Abandoned
- 2017-03-30 CN CN201780019968.0A patent/CN108834414A/en active Pending
- 2017-03-30 MA MA044603A patent/MA44603A/en unknown
- 2017-03-30 BR BR112018070229A patent/BR112018070229A2/en not_active Application Discontinuation
- 2017-03-30 US US16/091,542 patent/US20190119270A1/en not_active Abandoned
- 2017-03-30 SG SG11201807040WA patent/SG11201807040WA/en unknown
- 2017-03-30 EA EA201891866A patent/EA201891866A1/en unknown
- 2017-03-30 MX MX2018012255A patent/MX2018012255A/en unknown
- 2017-03-30 JP JP2018552177A patent/JP2019513730A/en active Pending
- 2017-03-30 KR KR1020187031898A patent/KR20180132804A/en unknown
- 2017-03-30 CA CA3015953A patent/CA3015953A1/en not_active Abandoned
-
2018
- 2018-09-03 IL IL261558A patent/IL261558A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017247558A1 (en) | 2018-09-13 |
| CA3015953A1 (en) | 2017-10-12 |
| WO2017174446A1 (en) | 2017-10-12 |
| EP3440079A1 (en) | 2019-02-13 |
| KR20180132804A (en) | 2018-12-12 |
| CN108834414A (en) | 2018-11-16 |
| BR112018070229A2 (en) | 2019-01-29 |
| MX2018012255A (en) | 2019-02-07 |
| JP2019513730A (en) | 2019-05-30 |
| MA44603A (en) | 2019-02-13 |
| EA201891866A1 (en) | 2019-04-30 |
| IL261558A (en) | 2018-10-31 |
| US20190119270A1 (en) | 2019-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201901716TA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201807040WA (en) | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors |